Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial

The race to develop an omicron-specific COVID-19 vaccine is in full swing. One day after Pfizer and BioNTech disclosed the start of their study, Moderna revealed it has dosed the first participant in a phase 2 trial that will study its omicron-specific booster candidate.